|Articles|May 16, 2022

VIDA Introduces New AI-Enabled Biomarker Services

VIDA Diagnostics, Inc. is introducing a new suite of retrospective data analysis services for clinical trial sponsors in response to growing demand for precision data to optimize lung treatment trials.

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Subscribe

Related Content

ACT Brief: Training Completion Versus Execution Readiness, AI Monitoring Agent Financial Value at Scale, and FDA Warning Letters and AI Oversight Gaps

ByAndy Studna, Senior Editor

August 13th 2026

Tufts CSDD Analysis Finds AI Clinical Monitoring Agent Can Generate Up to $21 Million in Net Financial Value Per Drug Development Program

ByAndy Studna, Senior Editor

August 12th 2026

Beyond Compliance: ProofPilot's Joseph Kim and Lauren Briggs on Making Clinical Trial Training Actually Work

ByOtis Johnson, PhD, MPA,Andy Studna, Senior Editor,Joseph Kim,Lauren Briggs

August 12th 2026

ACT Brief: Efficacy Ceiling Breakthrough in Autoimmune Disease, Early-Career Retention and Burnout Prevention, and PRV Program Catalyzing Rare Disease Investment

ByAndy Studna, Senior Editor

August 12th 2026

© photon_photo - © photon_photo - stock.adobe.com

The Career They Didn't Train For: Rethinking Early-Career Burnout in Clinical Research

ByMario Alejandro Castellanos Urdaibay, MD, MSc

August 11th 2026

VIDA Introduces New AI-Enabled Biomarker Services

Related Content

ACT Brief: Training Completion Versus Execution Readiness, AI Monitoring Agent Financial Value at Scale, and FDA Warning Letters and AI Oversight Gaps

Tufts CSDD Analysis Finds AI Clinical Monitoring Agent Can Generate Up to $21 Million in Net Financial Value Per Drug Development Program

Beyond Compliance: ProofPilot's Joseph Kim and Lauren Briggs on Making Clinical Trial Training Actually Work

ACT Brief: Efficacy Ceiling Breakthrough in Autoimmune Disease, Early-Career Retention and Burnout Prevention, and PRV Program Catalyzing Rare Disease Investment

The Career They Didn't Train For: Rethinking Early-Career Burnout in Clinical Research

Trending on Applied Clinical Trials Online

Tufts CSDD Analysis Finds AI Clinical Monitoring Agent Can Generate Up to $21 Million in Net Financial Value Per Drug Development Program

Beyond Compliance: ProofPilot's Joseph Kim and Lauren Briggs on Making Clinical Trial Training Actually Work

Breaking the Efficacy Ceiling in IBD and Beyond

ACT Brief: Efficacy Ceiling Breakthrough in Autoimmune Disease, Early-Career Retention and Burnout Prevention, and PRV Program Catalyzing Rare Disease Investment

The Career They Didn't Train For: Rethinking Early-Career Burnout in Clinical Research